Look Beyond the Bottle in Glaucoma Care
-
By
-
Christine Funke, MD
-
September 1, 2026
-
14 min
Clinical Report: Look Beyond the Bottle in Glaucoma Care
Background
Glaucoma is a serious condition that can lead to irreversible vision loss if not managed properly. Traditional treatment often relies on topical medications, which many patients struggle to adhere to, resulting in poor outcomes.
Data Highlights
No numerical data provided in the source material.
Key Findings
- 90% of patients do not adhere to their prescribed drop schedule.
- 50% of patients completely stop using their drops within 6 months.
- Up to 60% of patients are nonadherent to topical prostaglandin analog therapy.
- Patients who go 3 or more years without follow-up have an increased likelihood of vision loss.
- Topical medications can lead to side effects that affect adherence and quality of life.
Clinical Implications
Healthcare providers should consider the high rates of nonadherence when prescribing glaucoma treatments.
Conclusion
Emphasizing interventional methods may lead to better long-term outcomes for patients.
Related Resources & Content
- Williams AM, Liang HW, Lin HHS, Ophthalmol Glaucoma, 2025 -- Loss to follow-up and risk of incident blindness among patients with glaucoma in the IRIS Registry.
- optometric management — Look Beyond IOP in Glaucoma
- optometric management — LEADING OFF: Glaucoma Patient Resources Provide Support
- Optometric Management — Therapeutic Insights
- glaucoma physician — Revisiting Strategies for Glaucoma Education
- Look Beyond IOP in Glaucoma
- LEADING OFF: Glaucoma Patient Resources Provide Support
- Therapeutic Insights
- Preferred Practice Pattern® Guidelines: Ophthalmology
- Primary Open-Angle Glaucoma Preferred Practice Pattern® - Ophthalmology
- European Glaucoma Society
- World Glaucoma Association » Consensus 12
- Recommendations | Glaucoma: diagnosis and management | Guidance | NICE
- Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial - Ophthalmology
- Six-Year Rate of Visual Field Progression in the Laser in Glaucoma and Ocular Hypertension Trial - Ophthalmology
- Selective Laser Trabeculoplasty After Medical Treatment for Glaucoma or Ocular Hypertension | Trials | JAMA Ophthalmology | JAMA Network
- Selective Laser Trabeculoplasty Compared to Medication for Open‐Angle Glaucoma Patients: A Systematic Review and Meta‐Analysis - PMC
- DailyMed - IDOSE TR- travoprost intracameral implant
- Sustained-Release Intracameral Prostaglandin Analog Implants for Glaucoma: Comparative Review and Meta-Analysis of Bimatoprost and Travoprost Delivery Systems.
- Prospective 18-Month Study of Bimatoprost Intracameral Implant in Patients with Open-Angle Glaucoma or Ocular Hypertension in US Clinical Practice - PMC
- What are the benefits and risks of minimally invasive Schlemm's canal surgery for treating the common eye condition glaucoma? | Cochrane
- Hydrus microstent versus triple iStent inject W combined with phacoemulsification for glaucoma management: three-year outcomes | Eye
- Efficacy and safety of PreserFlo MicroShunt versus trabeculectomy in glaucoma patients: a systematic review, meta-analysis, and meta-regression of clinical outcomes and key covariates - PubMed
- Comparison of XEN gel stent for management of open-angle glaucoma: a systematic review and meta-analysis - PubMed
- Comparative Efficacy and Safety of XEN®45 Gel Stent versus Preserflo™ in Glaucoma: A Systematic Review and Meta-Analysis.
- Treatment Outcomes in the Tube Versus Trabeculectomy (TVT) Study After Five Years of Follow-up - PMC
- Primary Open-Angle Glaucoma Preferred Practice Pattern® - Ophthalmology
- Micropulse versus Slow Coagulation Transscleral Cyclophotocoagulation in Refractory Glaucoma: A Randomized Clinical Trial - ScienceDirect
- Micropulse Cyclophotocoagulation Versus Continuous Wave Cyclophotocoagulation: A Meta-Analysis - PubMed
Based on findings from:
Look Beyond the Bottle in Glaucoma Care
Christine Funke, MD. Ophthalmology Management, 2026.
https://www.ophthalmologymanagement.com/issues/2026/september/look-beyond-the-bottle-in-glaucoma-care
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
